Test Details: This testing, consisting of FLT3, NPM-1 and CEBPA, is recommended in the NCCN guidelines for determination of acute myeloid leukemia (AML) risk status in patients with cytogenetically normal AML. The presence of CEBPA gene mutations is associated with increased disease-free survival and overall survival. Mutations in NPM1 gene is a predictor of favourable prognosis and good response to induction chemotherapy. The presence of (FLT3) internal tandem duplication is associated with short disease-free survival. The mutations in exon 11 of the proto-oncogene c-Kit might play an important role in the pathogenesis and represent useful predictive genetic marker in AML.